A Potential Antibody–Drug Conjugate Targeting Human LIV1 for the Treatment of Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC), which accounts for 15 to 20% of incidents of breast cancer, is the only breast cancer subtype that lacks targeted treatments. It was reported in the literature that LIV1 was highly expressed in TNBC and other solid tumors. This makes LIV1 a potential target for...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Georg Thieme Verlag KG
2023-09-01
|
| Seri Bilgileri: | Pharmaceutical Fronts |
| Konular: | |
| Online Erişim: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1772703 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|